Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Indaptus Therapeutics, Inc.INDP · Entity 6530 | Director · Co-Chief Executive Officer | February 11, 2026 | February 13, 2026 |
| Intec Pharma Ltd.NTEC · Entity 146542 | Director · Chief Executive Officer | July 15, 2020 | July 17, 2020 |
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Director | September 10, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Indaptus Therapeutics, Inc.
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.60 · Expires 2029-08-08 | Direct | 0 |
Reported balance
After 2026-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-11 · Disposition to issuer · Disposed 3,033 · Balance 0 F1: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2029-08-08 | Direct | 3,033 |
Reported balance
After 2026-02-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-11 · Grant · Acquired 3,033 · Balance 3,033 F1: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.40 · Expires 2029-11-25 | Direct | 0 |
Reported balance
After 2026-02-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-11 · Disposition to issuer · Disposed 1,519 · Balance 0 F1: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2029-11-25 | Direct | 1,519 |
Reported balance
After 2026-02-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-11 · Grant · Acquired 1,519 · Balance 1,519 F1: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.30 · Expires 2030-07-27 | Direct | 0 |
Reported balance
After 2026-02-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-11 · Disposition to issuer · Disposed 12,136 · Balance 0 F1: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2030-07-27 | Direct | 12,136 |
Reported balance
After 2026-02-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-11 · Grant · Acquired 12,136 · Balance 12,136 F1: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged.
Intec Pharma Ltd.
Report date July 15, 2020 · Filed July 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2027-07-15 | Direct | 300,000 |
Reported balance
After 2020-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-15 · Grant · Acquired 300,000 · Balance 300,000 F1: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023.
Travere Therapeutics, Inc.
Report date September 10, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 91,500 |
Ending reported balance
After 2026-09-10 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-09-10 · Exercise / conversion · Acquired 10,000 · Balance 101,500 Row 2 · 2026-09-10 · Exercise / conversion · Acquired 10,000 · Balance 111,500 Row 3 · 2026-09-10 · Sale · Disposed 1,700 · Balance 109,800 F1: This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028. F2: The weighted average sale price for the transaction reported was $65.3917, and the range of prices were between $64.835 and $65.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 4 · 2026-09-10 · Sale · Disposed 1,200 · Balance 108,600 F1: This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028. F3: The weighted average sale price for the transaction reported was $66.15, and the range of prices were between $65.93 and $66.74. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 5 · 2026-09-10 · Sale · Disposed 14,000 · Balance 94,600 F1: This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028. F4: The weighted average sale price for the transaction reported was $67.4634, and the range of prices were between $66.93 and $67.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 6 · 2026-09-10 · Sale · Disposed 3,100 · Balance 91,500 F1: This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028. F5: The weighted average sale price for the transaction reported was $68.088, and the range of prices were between $67.94 and $68.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.44 · Expires 2027-05-17 | Direct | 0 |
Reported balance
After 2026-09-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-10 · Exercise / conversion · Disposed 10,000 · Balance 0 F6: The stock option is fully vested and exercisable. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.52 · Expires 2028-05-09 | Direct | 0 |
Reported balance
After 2026-09-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-10 · Exercise / conversion · Disposed 10,000 · Balance 0 F6: The stock option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028.
F2: The weighted average sale price for the transaction reported was $65.3917, and the range of prices were between $64.835 and $65.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3: The weighted average sale price for the transaction reported was $66.15, and the range of prices were between $65.93 and $66.74. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4: The weighted average sale price for the transaction reported was $67.4634, and the range of prices were between $66.93 and $67.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5: The weighted average sale price for the transaction reported was $68.088, and the range of prices were between $67.94 and $68.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F6: The stock option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 11, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.52 | $0.00 |
DisclosureSEC source: 0001506916-26-000004 · form4-09112026_040911.xml · derivative · entry 8 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001506916-26-000004 · form4-09112026_040911.xml · derivative · entry 7 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 3,100 | $68.09 | $211,072.80 |
DisclosureSEC source: 0001506916-26-000004 · form4-09112026_040911.xml · nonDerivative · entry 6 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,500 F1 · kind: This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028. F5 · price: The weighted average sale price for the transaction reported was $68.088, and the range of prices were between $67.94 and $68.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 14,000 | $67.46 | $944,487.60 |
DisclosureSEC source: 0001506916-26-000004 · form4-09112026_040911.xml · nonDerivative · entry 5 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,600 F1 · kind: This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028. F4 · price: The weighted average sale price for the transaction reported was $67.4634, and the range of prices were between $66.93 and $67.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 1,200 | $66.15 | $79,380.00 |
DisclosureSEC source: 0001506916-26-000004 · form4-09112026_040911.xml · nonDerivative · entry 4 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,600 F1 · kind: This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028. F3 · price: The weighted average sale price for the transaction reported was $66.15, and the range of prices were between $65.93 and $66.74. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 1,700 | $65.39 | $111,165.89 |
DisclosureSEC source: 0001506916-26-000004 · form4-09112026_040911.xml · nonDerivative · entry 3 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,800 F1 · kind: This sale was made pursuant to a written plan adopted on June 11, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person on May 17, 2017, with an expiration date of May 17, 2027, and on May 9, 2018, with an expiration date of May 9, 2028. F2 · price: The weighted average sale price for the transaction reported was $65.3917, and the range of prices were between $64.835 and $65.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $26.52 | $265,200.00 |
DisclosureSEC source: 0001506916-26-000004 · form4-09112026_040911.xml · nonDerivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $17.44 | $174,400.00 |
DisclosureSEC source: 0001506916-26-000004 · form4-09112026_040911.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 12,000 | $0.00 Strike: $42.26 | $0.00 |
DisclosureSEC source: 0001506916-26-000003 · form4-05212026_050510.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2036-05-19 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001506916-26-000003 · form4-05212026_050510.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,500 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionStock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $16.33 | $0.00 |
DisclosureSEC source: 0001506916-26-000001 · form4-05062026_080516.xml · derivative · entry 3 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2026-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 8,000 | $45.00 | $360,000.00 |
DisclosureSEC source: 0001506916-26-000001 · form4-05062026_080516.xml · nonDerivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,500 F1 · kind: This sale was made pursuant to a written plan adopted on November 17, 2025 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on May 18, 2016 with an expiration date of May 18, 2026. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 8,000 | $16.33 | $130,640.00 |
DisclosureSEC source: 0001506916-26-000001 · form4-05062026_080516.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantWarrants (right to buy) · Derivative | 12,136 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0001493152-26-006707 · ownership.xml · derivative · entry 6 Meckler Jeffrey A · CIK 0001506916 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,136 Underlying: Common Stock · 12,136 shares Expires 2030-07-27 F1 · price: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerWarrants (right to buy) · Derivative | 12,136 | Not disclosed Strike: $8.30 | Not disclosed |
DisclosureSEC source: 0001493152-26-006707 · ownership.xml · derivative · entry 5 Meckler Jeffrey A · CIK 0001506916 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,136 shares Expires 2030-07-27 F1 · price: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantWarrants (right to buy) · Derivative | 1,519 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0001493152-26-006707 · ownership.xml · derivative · entry 4 Meckler Jeffrey A · CIK 0001506916 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,519 Underlying: Common Stock · 1,519 shares Expires 2029-11-25 F1 · price: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerWarrants (right to buy) · Derivative | 1,519 | Not disclosed Strike: $29.40 | Not disclosed |
DisclosureSEC source: 0001493152-26-006707 · ownership.xml · derivative · entry 3 Meckler Jeffrey A · CIK 0001506916 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,519 shares Expires 2029-11-25 F1 · price: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantWarrants (right to buy) · Derivative | 3,033 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0001493152-26-006707 · ownership.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,033 Underlying: Common Stock · 3,033 shares Expires 2029-08-08 F1 · price: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerWarrants (right to buy) · Derivative | 3,033 | Not disclosed Strike: $47.60 | Not disclosed |
DisclosureSEC source: 0001493152-26-006707 · ownership.xml · derivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,033 shares Expires 2029-08-08 F1 · price: Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 21:01 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantCommon Stock | 216,617 | $2.03 | $439,732.51 |
DisclosureSEC source: 0001493152-25-029355 · ownership.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,929 F1 · shares: The Reporting Person acquired 216,617 shares of common stock pursuant to an amendment to his employment agreement, in connection with the signing of a securities purchase agreement, dated December 22, 2025. Read SEC document |
| July 27, 2025 Filed Jul 29, 2025 20:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantCommon Stock Warrants · Derivative | 12,136 | $8.30 Strike: $8.30 | $100,757.93 |
DisclosureSEC source: 0001641172-25-021376 · ownership.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,688 Underlying: Common Stock · 12,136 shares Expires 2030-07-27 F1 · shares: The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025. F1 · price: The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025. Read SEC document |
| July 27, 2025 Filed Jul 29, 2025 20:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantCommon Stock | 6,068 | $8.30 | $50,378.96 |
DisclosureSEC source: 0001641172-25-021376 · ownership.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,312 F1 · shares: The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025. F1 · price: The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025. Read SEC document |
| May 15, 2025 Filed May 16, 2025 23:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 19,500 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001415889-25-013500 · form4-05162025_070511.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2035-05-15 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 15, 2025 Filed May 16, 2025 23:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013500 · form4-05162025_070511.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,500 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 1,250 | $0.04 Strike: $355.20 | $46.25 |
DisclosureSEC source: 0001641172-25-003824 · ownership.xml · derivative · entry 6 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2025-06-28 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 1,563 | $0.04 Strike: $611.20 | $57.83 |
DisclosureSEC source: 0001641172-25-003824 · ownership.xml · derivative · entry 5 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,563 shares Expires 2026-04-04 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuersStock Option (right to buy) · Derivative | 1,500 | $0.04 Strike: $425.60 | $55.50 |
DisclosureSEC source: 0001641172-25-003824 · ownership.xml · derivative · entry 4 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2027-04-10 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 813 | $0.04 Strike: $425.60 | $30.08 |
DisclosureSEC source: 0001641172-25-003824 · ownership.xml · derivative · entry 3 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 813 shares Expires 2027-05-01 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 3,750 | $0.04 Strike: $24.60 | $138.75 |
DisclosureSEC source: 0001641172-25-003824 · ownership.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2027-07-15 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | Disposition to issuerStock Option (right to buy) · Derivative | 4,750 | $0.04 Strike: $536.00 | $175.75 |
DisclosureSEC source: 0001641172-25-003824 · ownership.xml · derivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,750 shares Expires 2027-12-11 F1 · price: The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 21:12 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantCommon Stock Warrants · Derivative | 42,553 | $1.18 Strike: $1.05 | $49,999.78 |
DisclosureSEC source: 0001493152-24-047808 · ownership.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,553 Underlying: Common Stock · 42,553 shares Expires 2029-11-25 F1 · price: The Reporting Person acquired 42,553 shares of common stock and 42,553 warrants to purchase common stock from the Issuer for an aggregate purchase price of $49,999.78. F1 · derivative.exercise_date: The Reporting Person acquired 42,553 shares of common stock and 42,553 warrants to purchase common stock from the Issuer for an aggregate purchase price of $49,999.78. Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 21:12 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantCommon stock | 42,553 | $1.18 | $49,999.78 |
DisclosureSEC source: 0001493152-24-047808 · ownership.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,859 F1 · price: The Reporting Person acquired 42,553 shares of common stock and 42,553 warrants to purchase common stock from the Issuer for an aggregate purchase price of $49,999.78. Read SEC document |
| October 09, 2024 Filed Oct 10, 2024 20:05 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001493152-24-040726 · ownership.xml · derivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-10-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in full on April 9, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:38 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionStock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $10.48 | $0.00 |
DisclosureSEC source: 0001415889-24-024117 · form4-10012024_121008.xml · derivative · entry 3 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2024-10-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:38 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 40,000 | $14.06 | $562,324.00 |
DisclosureSEC source: 0001415889-24-024117 · form4-10012024_121008.xml · nonDerivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,000 F1 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on October 8, 2014 with an expiration date of October 8, 2024. F2 · price: The weighted average sale price for the transaction reported was $14.0581, and the range of prices were between $13.782 and $14.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 00:38 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 40,000 | $10.48 | $419,200.00 |
DisclosureSEC source: 0001415889-24-024117 · form4-10012024_121008.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2024 Filed Aug 8, 2024 21:30 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantCommon Stock Warrants · Derivative | 84,932 | $1.83 Strike: $1.70 | $155,000.90 |
DisclosureSEC source: 0001493152-24-030839 · ownership.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,932 Underlying: Common Stock · 84,932 shares Expires 2029-08-08 F1 · price: The Reporting Person acquired 84,932 shares of common stock and 84,932 warrants to purchase common stock from the Issuer for an aggregate purchase price of $155,000.90. F1 · derivative.exercise_date: The Reporting Person acquired 84,932 shares of common stock and 84,932 warrants to purchase common stock from the Issuer for an aggregate purchase price of $155,000.90. Read SEC document |
| August 08, 2024 Filed Aug 8, 2024 21:30 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantCommon stock | 84,932 | $1.83 | $155,000.90 |
DisclosureSEC source: 0001493152-24-030839 · ownership.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,306 F1 · price: The Reporting Person acquired 84,932 shares of common stock and 84,932 warrants to purchase common stock from the Issuer for an aggregate purchase price of $155,000.90. Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 19,500 | $0.00 Strike: $6.82 | $0.00 |
DisclosureSEC source: 0001415889-24-012848 · form4-05102024_040536.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2034-05-07 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012848 · form4-05102024_040536.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,000 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| January 22, 2024 Filed Jan 23, 2024 21:15 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001493152-24-003450 · ownership.xml · derivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-01-22 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on January 22, 2025 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on January 22, 2027. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 13,500 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001209191-23-030961 · doc4.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2033-05-16 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030961 · doc4.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,500 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 21:05 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001493152-23-002021 · ownership.xml · derivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-18 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the total shares on January 18, 2024 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on January 18, 2026. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 13:00 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | PurchaseCommon stock | 9,600 | $1.90 | $18,240.00 |
DisclosureSEC source: 0001493152-22-033241 · ownership.xml · nonDerivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,374 Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 13:00 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | PurchaseCommon stock | 400 | $1.76 | $705.48 |
DisclosureSEC source: 0001493152-22-033241 · ownership.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,774 Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 13:00 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | PurchaseCommon stock | 10,308 | $2.80 | $28,862.40 |
DisclosureSEC source: 0001493152-22-025578 · ownership.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,374 Read SEC document |
| September 07, 2022 Filed Sep 8, 2022 13:00 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | PurchaseCommon stock | 8,632 | $2.57 | $22,184.24 |
DisclosureSEC source: 0001493152-22-025319 · ownership.xml · nonDerivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,066 Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 13:00 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | PurchaseCommon stock | 1,060 | $2.44 | $2,586.40 |
DisclosureSEC source: 0001493152-22-025319 · ownership.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,434 Read SEC document |
| June 06, 2022 Filed Jun 7, 2022 12:00 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | PurchaseCommon stock | 19,727 | $2.63 | $51,882.01 |
DisclosureSEC source: 0001493152-22-016027 · ownership.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,374 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.